Epilogix Publications

Connor GS, Labiner DM, Schabert VF, Weingarten M, Wade CT, Stern S, Becker DA. Greater need for treatment optimization in patients with epilepsy initiating adjunctive therapy: Results of a retrospective claims analysis of antiseizure medication drug load in the United States. Epilepsy Behav. 2024 Mar;152:109649. doi:10.1016/j.yebeh.2024.109649.

Schabert VF, Stern S, Ferrari L, Wade CT, Willke RJ, Hauser WA. Incidence of mental health conditions by seizure control among adults with epilepsy in the United States. Epilepsy Behav 2022 Aug 8;134:108865. doi:10.1016/j.yebeh.2022.108865.

Privitera M, Richy FF, Schabert VF. Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures. Epilepsy Behav 2022 Jan;126:108429. doi:10.1016/j.yebeh.2021.108429.

Schabert V, Shah S, Holmgren U, Cabrera C. Prescribing pathways to triple therapy in patients with chronic obstructive pulmonary disease in the United States. Ther Adv Respir Dis 2021 Jan-Dec;15:17534666211001018. doi:10.1177/17534666211001018.

• Becker DA, Stern S, Wade CT, Schabert VF. Cenobamate use as monotherapy: a retrospective claims-based analysis. Poster presented at the American Epilepsy Society (AES) Annual Meeting, December 1-3, 2023, Orlando, FL. https://doi.org/10.1212/WNL.0000000000205332

• Pellinen J, Wade CT, Stern S, Schabert VF, Elder CJ. Effectiveness of cenobamate in postsurgical patients: a retrospective claims-based analysis. Poster presented at the American Epilepsy Society (AES) Annual Meeting, December 1-3, 2023, Orlando, FL. https://doi.org/10.1212/WNL.0000000000205202

• Urban A, Stern S, Wade CT, Schabert VF. Comparative effectiveness of cenobamate in reducing hospitalizations in patients with focal seizures: a retrospective claims-based analysis. Poster presented at the American Epilepsy Society (AES) Annual Meeting, December 1-3, 2023, Orlando, FL. https://doi.org/10.1212/WNL.0000000000205198

• Weingarten M, Wade CT, Mandapati S, Schabert VF, Stern S. Retention of cenobamate in the real world. Poster presented at the American Epilepsy Society (AES) Annual Meeting, 2022, Nashville, TN. https://doi.org/10.1212/WNL.0000000000201803

• Falavigna M, Deyneli O, Seyam A, Mustafa N, Giorgi M, Gabriel Z, Goncalves S, Solorzano J, Vasnawala H, Schabert V, Mihajlović J. The net monetary benefit of introducing sodium-glucose cotransporter-2 inhibitors in middle-income countries. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) European Congress, 2022, Vienna, Austria. https://doi.org/10.1016/j.jval.2022.09.306

• Mehta R, Bahia L, Saif A, Musso C, Deyneli O, Subramaniam S, Gabriel Z, Goncalves S, Solorzano J, Vasnawala H, Schabert V, Mihajlović J. Impact of introducing sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes without complications. Poster presented at the International Diabetes Federation (IDF) Congress, 2022, Lisbon, Portugal. https://doi.org/10.1016/j.diabres.2023.110480

• Stern S, Wade CT, Schabert V, Mihajlović J. The budget impact of cenobamate for the treatment of uncontrolled focal epilepsy. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, 2021, Montreal, Canada. https://doi.org/10.1016/j.jval.2021.04.795

• Privitera M, Richy FF, Schabert VF. Meta-analysis/indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures. Poster presented at the American Epilepsy Society Annual Meeting, 2021, Chicago IL. Abstract

• Schabert VF, Rizk M, Longmire M. Evolving trials for the digital age. Chair and presenter (“Best practice operations for site EHR studies”) at the DIA 2020 Virtual Global Annual Meeting. Abstract

Chang CL, Schabert VF, Munakata J, Donga P, Abhyankar S, Reyes CM, Yim YM. Comparative healthcare costs in patients with metastatic melanoma in the USA. Melanoma Res. 2015 Aug;25(4):312-20. doi: 10.1097/CMR.0000000000000159.

Gao S, Barber B, Schabert V, Ferrufino C. Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe. Curr Med Res Opin. 2012 Jul;28(7):1111-8. doi: 10.1185/03007995.2012.694364.

Schabert VF, Ye X, Insinga RP, Singhal PK, Riedel AA. Five-Year Routine Cervical Cancer Screening Rates and Intervals in a United States Health Plan. Current Medical Research and Opinion 2008; 24(9):2429-2435.

2017 Lyman GH, Schabert VF, Philip PA, Stokes M, Bhurke S, Kuderer NM, Qadan A, Khorana AA. Thromboembolic events (TE) among patients with metastatic pancreatic ductal adenocarcinoma (mPDA) after chemotherapy (Chemo). Poster presented at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Forum, San Francisco CA.

2015 Lee YC, Mozaffari E, Schabert VF, Patel V, Casciano R. One-Year Incidence of Hospital Readmission in Hematopoietic Cell Transplant Recipients and Reasons for Readmissions. Poster presented at the 50th American Society of Health System Pharmacists Midyear Clinical Meeting, New Orleans LA.

2015 Schabert VF, Mozaffari E, Lee YC, Casciano R. Double-Stranded DNA (dsDNA) Viral Infections among Allogeneic Hematopoietic Cell Transplant (HCT) Recipients in the First Year after Transplant. Poster presented at the Annual Society of Hematology Annual Meeting, Orlando FL.

2015 Casciano R, Mozaffari E, Lee YC, Patel V, Schabert VF. Costs to U.S. Health Insurers For Hematopoietic Cell Transplant (HCT) Recipients With Double-Stranded DNA (dsDNA) Virus Infections Following Transplant. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress, Milan, Italy.

2014 Chen YJ, Schabert VF, Antao VP, De AP, Portera CC, Wang Y, Kamath T, Santos E. Treatment patterns and costs of neoadjuvant systemic therapies for early breast cancer (2006-2012): a retrospective analysis using claims data in the United States. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress, Amsterdam, Netherlands.

2014 Schabert VF, Chen YJ, Sun K, Wang Y. Relationship between progression-free survival and overall survival in hormone receptor negative metastatic breast cancer: a comparative effectiveness analysis using linked claims, EMR, and mortality records. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th International Meeting, Montreal, QC.

2014 Chang CL, Yim YM, Munakata J, Donga P, Reyes CM, Schabert VF. Comparative healthcare costs in patients with metastatic melanoma. Oral presentation at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL.

2014 Yim YM, Schabert VF, Munakata J, Chang CL, Donga P. The economic assessment of medical treatments and related adverse events in patients with metastatic melanoma. Poster presented at the Association of Managed Care Pharmacy (AMCP) 26th Annual Meeting, Tampa, FL.

2011 Lalla D, Pettetier EM, Goodman S, Brammer M, Schabert VF. A comparative effectiveness analysis of trastuzumab persistence between two adjuvant breast cancer treatment regimens among US health plan enrollees.  Poster presented at the San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX.

2011 Lalla D, Pettetier EM, Goodman S, Brammer M, Schabert VF. Patterns of lapatinib use among metastatic breast cancer patients in US managed care health plans.  Poster presented at the 14th Annual European Congress, International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Madrid, Spain.

2011 Lalla D, Pettetier EM, Goodman S, Brammer M, Schabert VF. Trastuzumab persistence between two adjuvant breast cancer treatment regimens among US health plan enrollees: a comparative effectiveness analysis.  Poster presented at the ESMO European Multidisciplinary Cancer Congress, Stockholm, Sweden.

Chiu YM, Lang HC, Lin HY, Yang MT, Fang CH, Yang YW, Schabert VF, Tang B. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan. Int J Rheum Dis. 2014 Dec;17 Suppl 3:9-19. doi: 10.1111/1756-185X.12539.

Curtis JR, Schabert VF, Harrison DJ, Yeaw J, Korn JR, Quach C, Yun H, Joseph GJ, Collier DH. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims. Clin Ther. 2014 Jul 1;36(7):996-1004. doi: 10.1016/j.clinthera.2014.05.062.

Curtis JR, Schabert VF, Yeaw J, Korn JR, Quach C, Harrison DJ, Yun H, Joseph GJ, Collier D. Use of a Validated Algorithm to Estimate the Annual Cost of Effective Biologic Treatment for Rheumatoid Arthritis. J Med Econ. 2014 Apr 22. doi: 10.3111/13696998.2014.914031.

Yeaw J, Watson C, Fox KM, Schabert VF, Goodman S, Gandra SR. Treatment Patterns Following Discontinuation of Adalimumab, Etanercept, and Infliximab in a US Managed Care Sample. Adv Ther. 2014 Mar 7. doi: 10.1007/s12325-014-0110-3.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J Manag Care Pharm. 2013;19(8):621-30. doi: 10.18553/jmcp.2013.19.8.621.

Schabert VF, Bruce B, Ferrufino CF, Globe DR, Harrison DJ, Lingala B, Fries JF. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study. Curr Med Res Opin. 2012 Apr;28(4):569-80. doi: 10.1185/03007995.2012.656844.

Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ 2012;15(2):264-75. doi: 10.3111/13696998.2011.644645.

Schabert VF, Harrison DJ, Globe DR, Goodman S, Burudpakdee C. Etanercept treatment for psoriatic disease. Am J Pharm Benefits. 2011;3(3):e51-e58.

2014 Morlock R, Storgard C, Schabert VF, Ogbonnaya A, Chevalier P, Hines D, Ramachandran S. Evaluation of symptom control among treated gout patients in the United States, United Kingdom, and Germany. Poster presented at the 2014 ACR/ARHP Annual Meeting, November 14-19, Boston, MA. Arthritis Rheum. 2014;66:S512. Abstract

2013 Schabert VF, Yeaw J, Korn JR, Quach C, Harrison DJ, Yun H, Joseph G, Collier D, Curtis JR. Long-term effectiveness and cost per effectively treated patient with biologics used in rheumatoid arthritis. Poster presented at the 2013 American College of Rheumatology Annual Meeting, San Diego, CA.

2013 Schabert VF, Korn JR, Bilir SP, DeKoven M, Harrison DJ, Joseph G. Cost per treated patient for biologics for rheumatoid arthritis (RA) using US claims data. Poster presented at the European League Against Rheumatism 2013 Congress, Madrid, Spain.

2013 Curtis JR, Schabert VF, Yeaw J, Korn JR, Quach C, Harrison DJ, Yun H, Joseph G, Collier D. Using a validated algorithm to evaluate the effectiveness and cost per effectively treated patient for biologics for rheumatoid arthritis (RA) in patients with employer provided health insurance. Poster presented at the European League Against Rheumatism 2013 Congress, Madrid, Spain.

2013 Schabert VF, Yeaw J, Korn JR, Quach C, Harrison DJ, Yun H, Joseph G, Collier D. Algorithm-based estimation of biologic effectiveness for rheumatoid arthritis. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 18th International Meeting, New Orleans, LA.

2013 Curtis JR, Schabert VF, Yeaw J, Korn J, Quach C, Harrison DJ, Yun H, Joseph G, Collier D. Using a validated algorithm to evaluate the effectiveness of biologics for rheumatoid arthritis in a commercial claims database. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 18th International Meeting, New Orleans, LA.

2013 Schabert VF, Yeaw J, Korn JR, Quach C, Harrison DJ, Yun H, Joseph G, Collier D, Curtis JR. Effectiveness of second line biologic use in rheumatoid arthritis after switching from first-line biologics. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 18th International Meeting, New Orleans, LA.

2013 Schabert VF, Yeaw J, Korn JR, Quach C, Harrison DJ, Yun H, Joseph G, Collier D, Curtis JR. Cost per treated patient for biologics across adult indications using claims data. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 18th International Meeting, New Orleans, LA.

2013 Curtis JR, Schabert VF, Yeaw J, Korn JR, Quach C, Harrison DJ, Yun H, Joseph G, Collier D. Using a validated, claims data based algorithm to evaluate the effectiveness of self-injected vs. infused biologics for rheumatoid arthritis claims data. Poster presented at the Academy of Managed Care Pharmacy 25th Annual Meeting, San Diego, CA.

2013 Schabert VF, Watson C, Burudpakdee C, Joseph G, Iverson P, Harrison DJ. Costs of tumor necrosis factor blockers per treated patient with psoriatic disease using real-world drug utilization data in a U.S. managed care population. Poster presented at the 71st American Academy of Dermatology Annual Meeting, Miami Beach, FL.

2012 Schabert VF, Watson C, Joseph G, Iversen P, Burudpakdee C, Harrison DJ. Costs of tumor necrosis factor blockers per treated rheumatoid arthritis patient using real-world drug data in a US managed care population. Poster presented at the 2012 American College of Rheumatology Annual Meeting, Washington, DC.

2012 Schabert VF, Fox KM, Watson C, Yeaw J, Goodman S, Gandra SR. Post-discontinuation treatment patterns for tumor necrosis factor-blockers in rheumatoid arthritis patients in the US. Poster presented at the European League Against Rheumatism 2012 Congress, Berlin, Germany.

2012 Schabert VF, Watson C, Fox KM, Gandra SR. Post-discontinuation treatment patterns for tumor necrosis factor (TNF)-blockers in US psoriasis patients. Poster presented at the 70th American Academy of Dermatology Annual Meeting, San Diego, CA.

2011 Schabert V, Gandra SR, Watson C, Fox KM, Yeaw J, Goodman S, Milev S, Harrison DJ.  Costs of tumor necrosis factor blockers per treated patient across adult indications using real-world data in US commercially-insured population.  Poster presented at the 14th Annual European Congress, International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Madrid, Spain.

2011 Schabert VF, Gandra S, Watson C, Yeaw J, Goodman S, Fox KM, Milev S, Harrison DJ.  Costs of tumor necrosis factor blockers per treated rheumatoid arthritis patient using real-world drug data in US commercially-insured population.  Poster presented at the ACR/ARHP Annual Scientific Meeting, Chicago, IL.

2011 Schabert VF, Gandra S, Watson C, Goodman S, Fox KM, Yeaw J, Milev S, Harrison DJ.  Comparing costs of tumor necrosis factor blockers per treated patient for psoriatic arthritis using real-world data in US managed care.  Poster presented at the ACR/ARHP Annual Scientific Meeting, Chicago, IL.

2010 Schabert VF, Bruce B, Ferrufino CF, Fries JF, Globe DR, Harrison DJ. Disability outcomes and dose escalation in rheumatoid arthritis patients treated with tumor necrosis factor blockers: a comparative effectiveness analysis.  Poster presented at the 13th Annual European Congress, International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Prague, Czech Republic.

2010 Makin C, Harrison DJ, Schabert VF, Goodman S. Methods for interpreting tumor necrosis factor (TNF) blocker dosing and treatment patterns from pharmacy and professional claims. Poster presented at ISPOR 15th International Meeting, Atlanta, GA.

2009 Schabert VF, Harrison DJ, Globe DR, Goodman S, Burudpakdee C. Correspondence between etanercept treatment patterns and dosing recommendations for psoriasis patients. Poster presented at the AAD summer scientific meeting, Boston, MA.

Miller LA, Burudpakdee C, Zagar A, Bhosle M, Reaney M, Schabert VF, Bruhn D. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany. J Med Econ. 2012;15(4):746-57. doi: 10.3111/13696998.2012.679756.

Wasserman J, Boyce-Smith G, Hopkins DS, Schabert VF, Davidson M, Ozminkowski RJ, Kennedy S. A comparison of diabetic patients’ self-reported health status with Hemoglobin A1c test results in 11 California health plans. Manag Care. 2001 Mar;10(3):58-62, 65-8, 70.

2011 Miller LA, Burudpakdee C, Zagar A, Bhosle M, Reaney M, Schabert VF.  Exenatide (BID) and liraglutide (QD) treatment patterns among patients with Type 2 diabetes in Germany.  Poster presented at the 16th Annual International Meeting, International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Baltimore, MD.

2002 Schabert VF, Frohlich J, Esposito D, Conklin JE, Boyd D, McAfee T. Comparing annual HbA1c testing, quarterly follow-up testing, and intervention effectiveness. Poster presented at the Academy for Health Services Research and Health Policy 2002 Annual Meeting.

2001 Schabert VF, Zhang M, Esposito D, Neslusan CA, Conklin JE, Cohen F. Treatment change following Hemoglobin A1c test results among diabetes patients. Poster presented at the Fourth Annual European Congress, International Society for Pharmacoeconomic and Outcomes Research, Cannes, France.

2001 Schabert VF, Neslusan CA, Conklin JE, Esposito D. Patient characteristics and drug treatment patterns associated with use of newer thiazolidinediones. Poster presented at the European Association for the Study of Diabetes, 37th Annual Meeting, Glasgow, Scotland.

2001 Schabert VF, Guo M, Conklin JE, Neslusan CA. An early look at thiazolidinedione (TZD) use in type 2 diabetes. Poster presented at the Sixth Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Arlington, VA.

Mark TL, Song X, Vandivort R, Duffy S, Butler J, Coffey R, Schabert VF. Characterizing substance abuse providers that treat adolescents. J Subst Abuse Treat. 2006 Jul;31(1):59-65.

2006 Schabert VF, Stein MB, Kenney TA, Bowers BW. Nonspecific psychological distress predicts increased healthcare utilization and expenditures in linked United States epidemiological surveys. Poster presented at the 14th Congress of European Psychiatry, Nice, France.

2002 Schabert VF, Esposito D, Bowers BW, Tillotson F. New Migraine Patients Have Lower Risk of ER and Inpatient Admission with Triptan Therapy and Higher Risk with Narcotic Therapy. Paper presented at the American Headache Society 44th Annual Meeting.

2002 Schabert VF, Esposito D, Bowers BW, Rousey AM, Tillotson F. Total healthcare expenditures for migraine patients associated with choice of drug therapy. Paper presented at the Seventh Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Arlington, VA.

2002 Schabert VF, Esposito D, Bowers BW, Rousey AM, Batenhorst AS. Migraine Prevalence and Associated Prescription Drug Treatments in a Private Insurance Claims Database. Poster presented at the American Academy of Neurology, 54th Annual Meeting, Denver, CO.

2014 Hill JW, Pokras SM, Foody JM, Schabert VF, Makin C, Nelson M. Primary Non-adherence to Antiplatelet Therapy After Hospitalization for Acute Coronary Syndrome (ACS) and Impact on Readmissions, Mortality, Health Care Use and Costs. Podium presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th International Meeting, Montreal, QC.

2007 Li J, Reaven NL, Funk S, Schabert VF, Lovett J. How influential are clinical guidelines for the evaluation of acute cardiac symptoms? Methodology for the investigation of National Coronary Disease Identification (INCIDENT). Poster presented at the Twelfth Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Arlington, VA.

2007 Li J, Reaven NL, Funk S, Schabert VF, Lovett J. Patients with acute anginal symptoms frequently do not receive initial electrocardiography: Results from the Investigation of National Coronary Disease Identification (INCIDENT). Poster presented at the American College of Cardiology 56th Annual Scientific Session, New Orleans, LA.

2007 Li J, Reaven NL, Funk S, Schabert VF, Lovett J. Coronary Intervention Rates Following Coronary Angiography Without Prior Stress Testing: Results From the Investigation of National Coronary Disease Identification (INCIDENT). Poster presented at the American College of Cardiology 56th Annual Scientific Session, New Orleans, LA.

2004 Schabert VF, Johann JS, Davis N. Telemonitors reduce emergent care visits for homebound congestive heart failure patients. Poster presented at the Eighth Annual Scientific Meeting of the Heart Failure Society of America.

2003 Schabert VF, Johann JS, Davis N. Telemonitors reduce hospital and ER admissions for homebound congestive heart failure (CHF) patients. Poster presented at the Eighth Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research, Arlington, VA.

Trocio JN, Brubaker L, Schabert VF, Bavendam T, Chen CI, Zou KH, Petrilla AA, Burgio KL. Fesoterodine prescription fill patterns and evaluation of the YourWay patient support plan for patients with overactive bladder symptoms and physicians. Postgrad Med. 2014 May;126(3):246-56. doi: 10.3810/pgm.2014.05.2773.

Schabert VF, Bavendam T, Goldberg EL, Trocio JN, Brubaker L. Challenges for managing overactive bladder and guidance for patient support. Am J Manag Care. 2009 Mar;15(4 Suppl):S118-22.

2009 Taylor P, Trocio J, Schabert VF, Goldberg EL, Bavendam T, Brubaker L. The Toviaz YourWay Plan: A multidimensional program for managing overactive bladder. Poster presented at the American Urogynecologic Society 30th Annual Scientific Meeting, Hollywood, FL.

2009 Taylor P, Goldberg EL, Schabert VF, Trocio J, Bavendam T. Development of a Multidimensional Approach to Managing Overactive Bladder. Poster presented at the American Academy of Physician Assistants 37th Annual Conference, San Diego, CA.

Marple BF, Roberts CS, Frytak JR, Schabert VF, Wegner JC, Bhattacharayya H, Piccirillo JF, Sanchez SP. Azithromycin extended release vs amoxicillin/clavulanate: symptom resolution in acute sinusitis. Am J Otolaryngol. 2010 Jan-Feb;31(1):1-8. doi: 10.1016/j.amjoto.2008.08.011.

2007 Schabert VF, Singhal, PK, Ye X. The incidence and healthcare cost of genital warts in a commercially insured population in the United States. Poster presented at the America’s Health Insurance Plans 2007 Medical Leadership Forum, Phoenix, AZ.

Pritchard D, Petrilla A, Hallinan S, Taylor DH Jr, Schabert VF, Dubois RW. What Contributes Most to High Health Care Costs? Health Care Spending in High Resource Patients. J Manag Care Spec Pharm. 2016 Feb;22(2):102-9. doi: 10.18553/jmcp.2016.22.2.102.

2014 Pritchard D, Petrilla A, Hallinan S, Taylor DH Jr., Schabert VF, Dubois RW. Healthcare spending patterns in high resource patients. Poster presented at the AcademyHealth Annual Research Meeting, San Diego, CA.

2014 Pritchard D, Petrilla A, Hallinan S, Taylor DH Jr., Schabert VF, Dubois RW. Healthcare spending patterns in high resource patients. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th International Meeting, Montreal, QC.

2011 Hess G, Benner JS, Schabert VF. New patient-level data from SENTINEL, ACA and recent commercial endeavours: implications for outcomes research. IMS symposium at the 16th Annual International Meeting, International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Baltimore, MD.

2011 Resnick J, Schabert VF. Opportunities and risks associated with Real-World Evidence. Podium presentation at the 2011 IMS Market Access Conference, New York, NY.

2010 Schabert VF, Mohr P, Ollendorf DA, Paul LD. Will comparative effectiveness research survive health reform?  IMS Symposium at 15th International Meeting, International Society of Pharmacoeconomics and Outcomes Research (ISPOR), Atlanta, GA.

2010 Glik R, Schabert VF. Commercial health plans and the evolving role of comparative effectiveness research.  Podium presentation at the IMS Market Access Conference., New York, NY.

2005 Schabert VF. Detecting, correcting, and preventing missed revenue opportunities in homecare. Invited presentation for the Texas Association for Homecare Winter Conference, Austin, TX.

2002 Schabert VF, Bott J, Tillotson B, Demars C, Rudolph BA. Measurement, risk adjustment, and public report of in-hospital complications. Poster presented at the Academy for Health Services Research and Health Policy 2002 Annual Meeting.

2000 Dixon RE, Schabert VF, Hopkins DS, Conklin, J. Claim and encounter databases for ambulatory care are incomplete and inaccurate. Poster presented at the Academy for Health Services Research (AHSR) 2000 Annual Meeting.

1999 Schabert VF. Performance measurement and quality improvement. Invited presentation for the BlueCross BlueShield Association HEDIS 2000 conference, Chicago, IL.

Goldberg EL, DeKoven M, Schabert VF, Coyle K. Patient medication adherence: The forgotten aspect of biologics. Biotechnol Healthc 2009 Jun;6(2):39-44.

2011 Schabert VF. Next steps for patient adherence. Invited keynote presentation at RxAdherence 2011, New Brunswick, NJ.

2009 Schabert VF, Dupclay L, Siddhartha R, Burudpakdee C, Goldberg E. Impact of intervention type on antihypertensive medication adherence effects.  Poster presented at Academy Health Annual Research Meeting, Chicago, IL.

2009 Schabert VF, Alibocus K, Frenzel A. Developing a successful strategy for medication adherence interventions. Invited presentation at the eyeforpharma Patient Relationship Marketing and Adherence conference, London.

2009 Taylor P, Goldberg EL, Schabert VF, Trocio J, Bavendam T. Development of a Multidimensional Approach to Managing Overactive Bladder. Poster presented at the American Academy of Physician Assistants 37th Annual Conference, San Diego, CA.

2009 Gwadry-Sridhar F, Manias E, Schabert VF, Shinogle J. Comparisons between the medication possession ratio (MPR) and gaps measures of medication compliance: are we selling ourselves short by relying on the MPR? Issue panel presentation at ISPOR 14th International Meeting, Orlando, FL.

2008 Schabert VF. The missing links for effective adherence interventions. Invited presentation at ECRM Patient Acquisition and Medication Adherence Conference, Scottsdale, AZ.

2008 Schabert VF, Drane A. Health behavior change: Leading models and their practical application. Workshop at ISPOR 13th International Meeting, Toronto.